Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for...
Cancer
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused...
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference
BOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in...
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023
Significant pipeline advancementsStrategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10BnKey senior management hires LONDON, UK /...
Poolbeg Pharma PLC Announces Appointment of Joint Broker
LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma Plc (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a biopharmaceutical company...
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
Exclusive Option Agreement to Acquire Orphan Drug Candidate for Behçet's DiseaseNovel therapeutic with Fast Track and Orphan DesignationLONDON, UK /...
Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company
MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #acquisition--Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced that it signed a definitive...
Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2024) - Cosmo Pharmaceuticals N.V. (SIX:...
Sona’s Cancer Therapy Creates a Systemic Immune Response in Murine Breast Cancer Model
Halifax, Nova Scotia--(Newsfile Corp. - April 29, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")...
Community Impact: Unite Iowa Adds 12,500 Programs to Unite Us Platform to Increase Access to Vital Community Resources
The state's leading coordinated care network, operated by CyncHealth Iowa, celebrates a milestone year serving Iowa residents using Unite Us'...
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency...
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Next safety cohort to begin escalated dosing soonOCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:...
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3...
Verspeeten Family Cancer Centre Unveiling Marks a Historic Milestone in Cancer Research and Treatment
LONDON, Ontario, April 29, 2024 (GLOBE NEWSWIRE) -- London Health Sciences Foundation (LHSF) is proud to announce the unveiling of...
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA...
Immodulon to Participate in the Wells Fargo Virtual Private Biotech Symposium
UXBRIDGE, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Immodulon, a late-stage clinical biotechnology company focused on developing a broad...
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage...
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused...